Please provide your email address to receive an email when new articles are posted on . Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among ...
The study included 1032 patients: 658 denosumab users and 374 oral bisphosphonate users. HealthDay News — For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a ...
LOS ANGELES, Dec 14 (Reuters) - Amgen Inc said on Friday that osteoporosis drug denosumab, the biotechnology company's most important new offering, increased bone strength in women receiving hormone ...
LOS ANGELES, May 28 (Reuters) - Amgen Inc said on Wednesday its experimental osteoporosis drug denosumab achieved greater bone density than Merck & Co Inc's Fosamax, but some analysts expressed ...
THOUSAND OAKS, Calif., Sept. 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and ...
The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations. Stoboclo and Osenvelt ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and mAbxience ...
Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related conditions. The Patels added, "With the addition of two denosumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results